Daniela Kaufer

• Explain the role of blood-brain barrier (BBB) dysfunction in neurological disease, including TGF-beta/ALK5-driven astrocyte activation, and identify BBB integrity as both a biomarker and therapeutic target in TBI, aging, and stress.
• Distinguish neuronal from non-neuronal (glial, vascular) mechanisms of brain plasticity, and analyze how stress-induced myelin remodeling and oligodendrocyte dynamics contribute to behavioral vulnerability and disease risk.
• Define resilience as an active, mechanistically distinct brain state, not merely the absence of pathology, and evaluate how individual variability in stress and injury responses creates both research challenges and therapeutic opportunities.
• Assess how AI-integrated, multimodal data pipelines, including behavioral phenotyping, EEG, calcium imaging, and spatial transcriptomics, can systematically characterize resilient versus susceptible phenotypes in preclinical models.
• Connect Kaufer’s translational research trajectory (including the Bakar Labs Fellowship model) to commercial and clinical development opportunities, and identify how non-neuronal brain targets can generate novel drug and biomarker endpoints.